Emily A. McKaige

Emily A. McKaige

Auto-generated profile, based on publicly available information

Emily A. McKaige

Department of Biomedical Sciences, Faculty of Health and Medical Science University of Copenhagen Denmark

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2020 in Autophagy
Verified
Journal Article
Closed access
ARAvnika Ruparelia
Avnika Ruparelia
EMEmily A. McKaige
Emily A. McKaige
CWCaitlin Williams
Caitlin Williams
KSKeith E. Schulze
Keith E. Schulze
MFMargit Fuchs
Margit Fuchs
RBRobert James Bryson-Richardson
Robert James Bryson-Richardson
Dominant de novo mutations in the co-chaperone BAG3 cause a severe form of myofibrillar myopathy, exhibiting progressive muscle weakness, muscle structural failure, and protein aggregation. To elucidate the mechanism of disease in, and identify therapies for, BAG3 myofibrillar myopathy, we generated two zebrafish models, one conditionally expressing BAG3P209L and one with a nonsense mutation in bag3. While transgenic BAG3P209L-expressing fish display protein aggregation, modeling the early phase of the disease, bag3-/- fish exhibit exercise dependent fiber disintegration, and reduced swimming activity, consistent with later stages of the disease. Detailed characterization of the bag3-/- fish, revealed an impairment in macroautophagic/autophagic activity, a defect we confirmed in BAG3 patient samples. Taken together, our data highlights that while BAG3P209L expression is sufficient to promote protein aggregation, it is the loss of BAG3 due to its sequestration within aggregates, which results in impaired autophagic activity, and subsequent muscle weakness. We therefore screened autophagy-promoting compounds for their effectiveness at removing protein aggregates, identifying nine including metformin. Further evaluation demonstrated metformin is not only able to bring about the removal of protein aggregates in zebrafish and human myoblasts but is also able to rescue the fiber disintegration and swimming deficit observed in the bag3−/- fish. Therefore, repurposing metformin provides a promising therapy for BAG3 myopathy. Abbreviations:ACTN: actinin, alpha; BAG3: BAG cochaperone 3; CRYAB: crystallin alpha B; DES: desmin; DMSO: dimethyl sulfoxide; DNAJB6: DnaJ heat shock protein family (Hsp40) member B6; dpf: days post fertilization; eGFP: enhanced green fluorescent protein; FDA: Food and Drug Administration; FHL1: four and a half LIM domains 1; FLNC: filamin C; hpf: hours post-fertilization; HSPB8: heat shock protein family B [small] member 8; LDB3/ZASP: LIM domain binding 3; MYOT: myotilin; TTN: titin; WT: wild-type.

19 December 2018 in Human Molecular Genetics
Verified
Journal Article
Closed access
PDF file
AWAlasdair J Wood
Alasdair J Wood
NCNaomi Cohen
Naomi Cohen
VJVeronica Joshi
Veronica Joshi
MLMei Li
Mei Li
ACAdam Costin
Adam Costin
PCPeter D. Currie
Peter D. Currie
Deficiency of muscle basement membrane (MBM) component laminin-α2, leads to muscular dystrophy congenital type 1a MDC1a, a currently untreatable myopathy. Laminin-α2 has two main binding partners within the MBM, dystroglycan and integrin. Integrins co-ordinate both cell adhesion and signalling, however there is little mechanistic insight into integrin’s function at the MBM. In order to study integrin’s role in basement membrane development and how this relates to the MBM’s capacity to handle force, an itgβ1.b-/- zebrafish line was created. Histological examination revealed increased extracellular matrix (ECM) deposition at the MBM in the itgβ1.b-/- fish, when compared to controls. Surprisingly, both laminin and collagen proteins were found to be increased in expression at the MBM of the itgβ1.b-/-larvae, when compared to controls. This increase in extracellular matrix components resulted in a decrease in myotomal elasticity as determined by novel passive force analyses. To determine if it was possible to control ECM deposition at the MBM by manipulating integrin activity, RGD peptide, a potent inhibitor of integrin-β1, was injected into in a zebrafish model of MDC1a. As postulated an increase in laminin and collagen was observed in the lama2-/- mutant MBM. Importantly, there was also an improvement in fibre stability at the MBM, judged by a reduction in fibre pathology. These results therefore show that, blocking ITGβ1 signalling increases ECM deposition at the MBM, a process that could be potentially exploited for treatment of MDC1a.

22 November 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
OVOliver B. Vad
Oliver B. Vad
CPChristian Paludan‐Müller
Christian Paludan‐Müller
SDSøren Z. Diederichsen
Søren Z. Diederichsen
EMEmily A. McKaige
Emily A. McKaige
LMLaia M. Monfort
Laia M. Monfort
MOMorten Olesen
Morten Olesen
Background: While atrial fibrillation (AF) is a key risk factor for stroke, recent studies have suggested that atrial cardiomyopathy may also increase stroke risk in the absence of AF. This study aimed to evaluate genetic determinants for left atrial (LA) function and volumes and risk of stroke. Methods and Results: Polygenic scores (PGSs) for LA measures were constructed and used in 380 017 individuals in the UK Biobank, without history of ischemic stroke, systemic arterial embolism, or AF at enrollment. Risk of ischemic stroke was estimated using time‐to‐event models, considering all‐cause death and incident AF as competing events. Systemic arterial embolism was investigated as a secondary end point. The PGS for LA passive emptying fraction was associated with risk of ischemic stroke. Individuals with a PGS for LA passive emptying fraction in the lowest quartile had a hazard ratio (HR) of 1.12 for ischemic stroke compared with those in the top quartile ( P =0.004). These associations were robust in a subgroup free of prevalent cardiovascular disease at baseline (HR for lowest quartile versus top quartile, 1.22; P <0.001). No associations were found for 4 other PGSs for LA measures or for risk of systemic arterial embolism. Two‐sample Mendelian randomization was conducted between LA measures and cardioembolic stroke and indicated a protective effect of higher LA functional measurements. Conclusions: The PGS for LA passive emptying fraction was significantly associated with incident ischemic stroke when considering AF as a competing risk. Consistent results were found in Mendelian randomization analyses. These findings suggest that atrial dysfunction may influence stroke risk independently of AF.

15 April 2024 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
EMEmily A McKaige
Emily A McKaige
CLClara Lee
Clara Lee
VCVanessa Calcinotto
Vanessa Calcinotto
SGSaveen Giri
Saveen Giri
SCSimon Crawford
Simon Crawford
RBRobert James Bryson-Richardson
Robert James Bryson-Richardson
Mutations in DNAJB6 are a well-established cause of limb girdle muscular dystrophy type D1 (LGMD D1). Patients with LGMD D1 develop progressive muscle weakness with histology showing fibre damage, autophagic vacuoles, and aggregates. Whilst there are many reports of LGMD D1 patients, the role of DNAJB6 in the muscle is still unclear. In this study, we developed a loss of function zebrafish model in order to investigate the role of Dnajb6. Using a double dnajb6a and dnajb6b mutant model, we show that loss of Dnajb6 leads to a late onset muscle weakness. Interestingly, we find that adult fish lacking Dnajb6 do not have autophagy or myofibril defects, however, they do show mitochondrial changes and damage. This study demonstrates that loss of Dnajb6 causes mitochondrial defects and suggests that this contributes to muscle weakness in LGMD D1. These findings expand our knowledge of the role of Dnajb6 in the muscle and provides a model to screen novel therapies for LGMD D1.

12 March 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
ARAvnika Ruparelia
Avnika Ruparelia
EMEmily A. McKaige
Emily A. McKaige
CWCaitlin Williams
Caitlin Williams
KSKeith E. Schulze
Keith E. Schulze
MFMargit Fuchs
Margit Fuchs
RBRobert James Bryson-Richardson
Robert James Bryson-Richardson
Dominant de novo mutations in the co-chaperone BAG3 cause a severe form of myofibrillar myopathy, exhibiting progressive muscle weakness, muscle structural failure, and protein aggregation. To identify therapies we generated two zebrafish models, one conditionally expressing BAG3 P209L and one with a nonsense mutation in bag3 . Whilst transgenic BAG3 P209L expressing fish display protein aggregation, modelling the early phase of the disease, bag3 −/− fish demonstrate impaired autophagic activity, exercise dependent fibre disintegration, and reduced swimming activity, consistent with later stages. We confirmed the presence of impaired autophagy in patient samples and screened autophagy promoting compounds for their effectiveness at removing protein aggregates, identifying nine including Metformin. Further evaluation demonstrated Metformin is not only able to remove the protein aggregates in zebrafish and human myoblasts but is also able to rescue the fibre disintegration and swimming deficit observed in the bag3 −/− fish. Therefore, repurposing Metformin provides a promising therapy for BAG3 myopathy.